Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19278636 | DOSAGE REGIMENS FOR BENZGALANTAMINE | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19263324 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | July 2025 | January 2026 | Allow | 6 | 1 | 0 | No | No |
| 19249959 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | June 2025 | October 2025 | Allow | 4 | 1 | 0 | No | No |
| 19225991 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | June 2025 | November 2025 | Allow | 5 | 1 | 0 | No | No |
| 19096247 | (S)-2-((S)-(2-ETHOXYPHENOXY)(PHENYL)METHYL)-4-NITROSOMORPHOLINE | March 2025 | January 2026 | Allow | 9 | 1 | 1 | No | No |
| 19055916 | METHODS OF TREATING MIGRAINE | February 2025 | November 2025 | Allow | 9 | 1 | 1 | No | No |
| 19045070 | METHODS FOR TREATING A FATTY LIVER DISEASE | February 2025 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 19030296 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | January 2025 | January 2026 | Allow | 12 | 2 | 0 | Yes | No |
| 18968681 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | December 2024 | November 2025 | Abandon | 11 | 2 | 0 | Yes | No |
| 18958449 | Compositions And Methods For The Treatment Of Depression | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18950383 | Oral Brexanolone Compositions and Methods of Preparation and Use | November 2024 | February 2026 | Allow | 14 | 3 | 0 | No | Yes |
| 18948977 | Compositions and Methods for Treatment and Prevention of Actinic Keratosis Using Copper Chlorin | November 2024 | July 2025 | Allow | 8 | 1 | 1 | No | No |
| 18935332 | SOLID FORMS OF MACROCYCLIC COMPOUNDS, SALTS AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE SAME | November 2024 | July 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18913072 | METHODS OF TREATING MIGRAINE | October 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18913492 | METHODS OF TREATING MIGRAINE | October 2024 | November 2025 | Allow | 13 | 3 | 1 | No | No |
| 18817153 | Methods of Treatment With an Iboga Alkaloid | August 2024 | July 2025 | Allow | 10 | 2 | 1 | No | No |
| 18811171 | Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity | August 2024 | November 2024 | Allow | 3 | 1 | 0 | No | No |
| 18811674 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18811682 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18796081 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18778617 | AGENTS THAT TARGET TELOMERASE REVERSE TRANSCRIPTASE (TERT) FOR TREATING CANCER AND SENSITIZING CANCER CELLS TO GENOTOXIC THERAPY | July 2024 | June 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18678224 | BERBERINE ALPHA-KETOGLUTARATE SALT, CRYSTALLINE FORM, METHODS OF PREPARATION AND APPLICATIONS THEREOF | May 2024 | March 2025 | Allow | 9 | 1 | 1 | No | No |
| 18674761 | PHARMACEUTICAL COMPOSITIONS COMPRISING A TOLFENAMIC ACID | May 2024 | December 2024 | Allow | 7 | 1 | 0 | No | No |
| 18670041 | COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN | May 2024 | March 2025 | Allow | 10 | 2 | 1 | No | No |
| 18670627 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | September 2024 | Allow | 4 | 2 | 0 | Yes | No |
| 18669417 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | May 2024 | July 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18659413 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | May 2024 | December 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18620036 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | March 2024 | June 2024 | Allow | 3 | 0 | 0 | No | No |
| 18615452 | Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity | March 2024 | August 2024 | Allow | 5 | 1 | 1 | No | No |
| 18438118 | Antimicrobial Compositions and Related Methods of Use | February 2024 | July 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18436555 | Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response | February 2024 | November 2025 | Allow | 21 | 2 | 0 | No | No |
| 18428937 | Compositions And Methods For The Treatment Of Depression | January 2024 | July 2024 | Allow | 5 | 2 | 0 | No | No |
| 18428542 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | January 2024 | October 2024 | Allow | 8 | 2 | 1 | No | No |
| 18422531 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | January 2024 | September 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18421519 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | January 2024 | July 2024 | Allow | 6 | 2 | 0 | No | No |
| 18414250 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | January 2024 | May 2025 | Allow | 16 | 1 | 0 | No | No |
| 18407337 | PHARMACEUTICAL COMPOSITION | January 2024 | August 2025 | Allow | 19 | 1 | 0 | No | No |
| 18397220 | BUPROPION AND DEXTROMETHORPHAN FOR REDUCTION OF SUICIDE RISK IN DEPRESSION PATIENTS | December 2023 | April 2025 | Allow | 16 | 1 | 0 | No | No |
| 18541574 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | December 2023 | March 2025 | Allow | 15 | 3 | 0 | Yes | No |
| 18538866 | AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I | December 2023 | March 2026 | Abandon | 27 | 1 | 1 | No | No |
| 18533619 | METHODS OF INHIBITING CYCLOOXYGENASE (COX) USING TOLTERODINE | December 2023 | October 2024 | Allow | 10 | 2 | 1 | No | No |
| 18529506 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | December 2023 | August 2025 | Allow | 21 | 1 | 0 | No | No |
| 18517512 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | November 2023 | August 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18510986 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | November 2023 | May 2024 | Abandon | 6 | 1 | 0 | No | No |
| 18510882 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | November 2023 | November 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18509114 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases | November 2023 | September 2025 | Allow | 22 | 1 | 1 | No | No |
| 18502166 | ADMINISTRATION OF TESTOSTERONE COMPOSITIONS | November 2023 | September 2025 | Allow | 22 | 2 | 0 | No | No |
| 18501967 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | November 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18501966 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18385468 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE | October 2023 | June 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18490993 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | October 2023 | December 2025 | Allow | 26 | 2 | 1 | No | No |
| 18489685 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | October 2023 | June 2024 | Abandon | 8 | 2 | 0 | No | No |
| 18483952 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | October 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18477175 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | September 2023 | April 2024 | Allow | 6 | 1 | 0 | No | No |
| 18373816 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | September 2023 | September 2025 | Allow | 24 | 2 | 0 | No | No |
| 18466595 | NEOADJUVANT CHEMOTHERAPY INDUCES BREAST CANCER METASTASIS THROUGH A TMEM-MEDIATED MECHANISM | September 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18239195 | FORMULATIONS AND USES THEREOF | August 2023 | June 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18236345 | Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same | August 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18235986 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18447117 | Dynamic Changes In Circulating Free RNA Of Neural Tumors | August 2023 | September 2024 | Allow | 13 | 0 | 0 | No | No |
| 18230693 | Medical Use of Pharmaceutical Combination or Composition | August 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18359858 | SIRNA, MEDICAL COMPOSITIONS, AND METHODS FOR TREATING DIABETES USING THE SAME | July 2023 | August 2025 | Allow | 25 | 2 | 1 | No | No |
| 18359214 | Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | July 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18355232 | EP4 INHIBITORS AND USE THEREOF | July 2023 | April 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18354215 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18219633 | USE OF ISOTHIOCYANATE IN SMOKELESS TOBACCO PRODUCTS | July 2023 | August 2025 | Allow | 26 | 2 | 1 | Yes | No |
| 18347970 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | July 2023 | March 2025 | Allow | 21 | 4 | 0 | No | No |
| 18342157 | Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase | June 2023 | August 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18342190 | VACCINE ADJUVANTS AND FORMULATIONS | June 2023 | July 2025 | Allow | 25 | 1 | 1 | No | No |
| 18335315 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | June 2023 | April 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18333944 | TREATMENT OF DEPRESSION IN CERTAIN PATIENT POPULATIONS | June 2023 | November 2023 | Allow | 5 | 1 | 0 | No | No |
| 18323714 | BUPROPION AND DEXTROMETHORPHAN FOR REDUCTION OF SUICIDE RISK IN DEPRESSION PATIENTS | May 2023 | December 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18199475 | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | May 2023 | May 2025 | Allow | 24 | 1 | 1 | No | No |
| 18196377 | HUNGER SUPPRESSION | May 2023 | April 2025 | Allow | 23 | 2 | 0 | No | No |
| 18140864 | SOLID DISPERSION FORMS OF RIFAXIMIN | April 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18301754 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | April 2023 | August 2023 | Allow | 4 | 1 | 0 | No | No |
| 18248499 | SODIUM OXYBATE TO TREAT IDIOPATHIC HYPERSOMNIA | April 2023 | November 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18298157 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | April 2023 | June 2025 | Allow | 26 | 1 | 1 | No | No |
| 18132268 | AMINO ACID DERIVATIVES CONTAINING A DISULFANYL GROUP AS AN INHIBITOR OF NEP AND APN FOR THE PREVENTION AND TREATMENT OF TRIGEMINAL NERVE PAIN | April 2023 | August 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18247261 | ALLOSTERIC AKT INHIBITORS FOR USE IN THE TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA | March 2023 | September 2025 | Allow | 30 | 0 | 0 | No | No |
| 18190843 | Next Generation FKBP52 Targeting Drugs for the Treatment of Prostate and Breast Cancer | March 2023 | April 2025 | Allow | 25 | 1 | 1 | No | No |
| 18188894 | Compositions And Methods For The Treatment Of Depression | March 2023 | January 2024 | Allow | 10 | 2 | 0 | No | No |
| 18124774 | ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18185697 | ENERGY-EFFICIENT SOLVENT-FREE METHOD FOR PRODUCING METAL CHELATES | March 2023 | April 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18117059 | COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE | March 2023 | April 2025 | Allow | 25 | 2 | 0 | No | No |
| 18173291 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | February 2023 | June 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18042632 | Methods of Treatment with Myosin Modulator | February 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18171126 | THERAPEUTIC AGENT FOR FATTY LIVER DISEASE | February 2023 | February 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18168382 | COMPOSITIONS AND METHODS FOR TREATMENT OF OBESITY | February 2023 | December 2025 | Allow | 34 | 1 | 0 | No | No |
| 18106363 | ANTI-METHANOGENIC LOVASTATIN ANALOGS OR DERIVATIVES AND USES THEREOF | February 2023 | March 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18104045 | AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR | January 2023 | October 2025 | Abandon | 33 | 1 | 1 | No | No |
| 18018951 | Digestive Lipase Activity Inhibitor, Blood Triglyceride Concentration Increase Inhibitor, and Fat Absorption Inhibitor | January 2023 | February 2026 | Allow | 37 | 1 | 0 | No | No |
| 18159270 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | January 2023 | October 2025 | Allow | 32 | 1 | 1 | Yes | No |
| 18158268 | TREATMENT OF DEPRESSION IN CERTAIN PATIENT POPULATIONS | January 2023 | May 2023 | Allow | 4 | 1 | 0 | No | No |
| 18017591 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS | January 2023 | December 2025 | Allow | 34 | 1 | 0 | No | No |
| 18095691 | Tamper Resistant Pharmaceutical Formulations | January 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 18150933 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE | January 2023 | March 2026 | Abandon | 38 | 2 | 1 | No | No |
| 18092800 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | January 2023 | August 2024 | Allow | 19 | 0 | 0 | No | No |
| 18092818 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | January 2023 | August 2025 | Allow | 31 | 1 | 1 | No | No |
| 18089752 | THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE | December 2022 | August 2025 | Allow | 32 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEDDINGTON, KEVIN E.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WEDDINGTON, KEVIN E works in Art Unit 1629 and has examined 1,165 patent applications in our dataset. With an allowance rate of 77.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner WEDDINGTON, KEVIN E's allowance rate of 77.9% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WEDDINGTON, KEVIN E receive 1.59 office actions before reaching final disposition. This places the examiner in the 30% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WEDDINGTON, KEVIN E is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +13.0% benefit to allowance rate for applications examined by WEDDINGTON, KEVIN E. This interview benefit is in the 50% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 35.3% of applications are subsequently allowed. This success rate is in the 79% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 72.8% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 89% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 88.6% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 80.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.8% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 71% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 45.2% of allowed cases (in the 97% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.